JP2018523686A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018523686A5 JP2018523686A5 JP2018508741A JP2018508741A JP2018523686A5 JP 2018523686 A5 JP2018523686 A5 JP 2018523686A5 JP 2018508741 A JP2018508741 A JP 2018508741A JP 2018508741 A JP2018508741 A JP 2018508741A JP 2018523686 A5 JP2018523686 A5 JP 2018523686A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tumor
- diabody
- cell carcinoma
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 46
- 206010028980 Neoplasm Diseases 0.000 claims description 29
- 229920001184 polypeptide Polymers 0.000 claims description 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- 201000011510 cancer Diseases 0.000 claims description 15
- 206010060862 Prostate cancer Diseases 0.000 claims description 12
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims description 10
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 10
- 208000005017 glioblastoma Diseases 0.000 claims description 10
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 10
- 201000001441 melanoma Diseases 0.000 claims description 10
- 201000002528 pancreatic cancer Diseases 0.000 claims description 10
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 10
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 9
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 9
- 206010034811 Pharyngeal cancer Diseases 0.000 claims description 9
- 206010038389 Renal cancer Diseases 0.000 claims description 9
- 201000010982 kidney cancer Diseases 0.000 claims description 9
- 230000027455 binding Effects 0.000 claims description 7
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 206010009944 Colon cancer Diseases 0.000 claims 12
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 12
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 12
- 206010017758 gastric cancer Diseases 0.000 claims 12
- 201000011549 stomach cancer Diseases 0.000 claims 12
- 206010005003 Bladder cancer Diseases 0.000 claims 8
- 208000003174 Brain Neoplasms Diseases 0.000 claims 8
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 8
- 206010029260 Neuroblastoma Diseases 0.000 claims 8
- 206010033128 Ovarian cancer Diseases 0.000 claims 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 8
- 206010039491 Sarcoma Diseases 0.000 claims 8
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 239000003937 drug carrier Substances 0.000 claims 8
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 8
- 201000005202 lung cancer Diseases 0.000 claims 8
- 208000020816 lung neoplasm Diseases 0.000 claims 8
- 208000037819 metastatic cancer Diseases 0.000 claims 8
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 8
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 8
- 201000005112 urinary bladder cancer Diseases 0.000 claims 8
- 208000030507 AIDS Diseases 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 4
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 claims 4
- 206010003571 Astrocytoma Diseases 0.000 claims 4
- 206010005949 Bone cancer Diseases 0.000 claims 4
- 208000018084 Bone neoplasm Diseases 0.000 claims 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims 4
- 208000005243 Chondrosarcoma Diseases 0.000 claims 4
- 201000009047 Chordoma Diseases 0.000 claims 4
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 4
- 206010014967 Ependymoma Diseases 0.000 claims 4
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 4
- 208000021309 Germ cell tumor Diseases 0.000 claims 4
- 208000009164 Islet Cell Adenoma Diseases 0.000 claims 4
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 4
- 208000000172 Medulloblastoma Diseases 0.000 claims 4
- 206010027406 Mesothelioma Diseases 0.000 claims 4
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 4
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 4
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 4
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 4
- 206010033963 Parathyroid tumour Diseases 0.000 claims 4
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 208000008938 Rhabdoid tumor Diseases 0.000 claims 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims 4
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 4
- 206010057644 Testis cancer Diseases 0.000 claims 4
- 208000000728 Thymus Neoplasms Diseases 0.000 claims 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 4
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 4
- 210000004556 brain Anatomy 0.000 claims 4
- 201000010881 cervical cancer Diseases 0.000 claims 4
- 208000011654 childhood malignant neoplasm Diseases 0.000 claims 4
- 208000009060 clear cell adenocarcinoma Diseases 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 201000011523 endocrine gland cancer Diseases 0.000 claims 4
- 230000003352 fibrogenic effect Effects 0.000 claims 4
- 208000003884 gestational trophoblastic disease Diseases 0.000 claims 4
- 201000010536 head and neck cancer Diseases 0.000 claims 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 4
- 238000001990 intravenous administration Methods 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 239000007788 liquid Substances 0.000 claims 4
- 208000030883 malignant astrocytoma Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 206010027191 meningioma Diseases 0.000 claims 4
- 230000001394 metastastic effect Effects 0.000 claims 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims 4
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 4
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 210000000578 peripheral nerve Anatomy 0.000 claims 4
- 208000028591 pheochromocytoma Diseases 0.000 claims 4
- 201000002267 posterior uveal melanoma Diseases 0.000 claims 4
- 230000000069 prophylactic effect Effects 0.000 claims 4
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 4
- 201000000849 skin cancer Diseases 0.000 claims 4
- 201000011096 spinal cancer Diseases 0.000 claims 4
- 208000014618 spinal cord cancer Diseases 0.000 claims 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 4
- 206010042863 synovial sarcoma Diseases 0.000 claims 4
- 201000003120 testicular cancer Diseases 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 208000008732 thymoma Diseases 0.000 claims 4
- 210000001685 thyroid gland Anatomy 0.000 claims 4
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 4
- 208000017997 tumor of parathyroid gland Diseases 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 206010024612 Lipoma Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 description 14
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 238000000375 direct analysis in real time Methods 0.000 description 12
- 238000012063 dual-affinity re-targeting Methods 0.000 description 12
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 241000282567 Macaca fascicularis Species 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 4
- 210000004986 primary T-cell Anatomy 0.000 description 4
- 231100000416 LDH assay Toxicity 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015861 cell surface binding Effects 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562206051P | 2015-08-17 | 2015-08-17 | |
| US62/206,051 | 2015-08-17 | ||
| US201662280318P | 2016-01-19 | 2016-01-19 | |
| US62/280,318 | 2016-01-19 | ||
| PCT/US2016/046680 WO2017030926A1 (en) | 2015-08-17 | 2016-08-12 | Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018523686A JP2018523686A (ja) | 2018-08-23 |
| JP2018523686A5 true JP2018523686A5 (OSRAM) | 2019-08-08 |
Family
ID=58051498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018508741A Pending JP2018523686A (ja) | 2015-08-17 | 2016-08-12 | Ｂ７‐ｈ３及びｃｄ３に結合できる二重特異性１価ダイアボディ並びにその使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20190002563A1 (OSRAM) |
| EP (1) | EP3337507A4 (OSRAM) |
| JP (1) | JP2018523686A (OSRAM) |
| KR (1) | KR20180038045A (OSRAM) |
| CN (1) | CN107921130A (OSRAM) |
| AU (1) | AU2016307955A1 (OSRAM) |
| CA (1) | CA2995709A1 (OSRAM) |
| CL (1) | CL2018000422A1 (OSRAM) |
| CO (1) | CO2018001485A2 (OSRAM) |
| CR (1) | CR20180105A (OSRAM) |
| EA (1) | EA201890443A1 (OSRAM) |
| EC (1) | ECSP18011248A (OSRAM) |
| HK (1) | HK1249423A1 (OSRAM) |
| IL (1) | IL257562A (OSRAM) |
| MA (1) | MA42665A (OSRAM) |
| MX (1) | MX2018001954A (OSRAM) |
| PE (1) | PE20181066A1 (OSRAM) |
| PH (1) | PH12018500363A1 (OSRAM) |
| TW (1) | TW201718652A (OSRAM) |
| WO (1) | WO2017030926A1 (OSRAM) |
| ZA (1) | ZA201800955B (OSRAM) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3152235B1 (en) * | 2014-05-29 | 2021-08-25 | MacroGenics, Inc. | Tri-specific binding molecules and methods of use thereof |
| AR101997A1 (es) * | 2014-09-26 | 2017-01-25 | Macrogenics Inc | Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos |
| SG11201804839WA (en) | 2015-12-14 | 2018-07-30 | Macrogenics Inc | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
| US11459394B2 (en) | 2017-02-24 | 2022-10-04 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
| IL269826B1 (en) | 2017-04-11 | 2025-09-01 | Inhibrx Inc | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
| IL302613B2 (en) * | 2017-09-08 | 2025-04-01 | Maverick Therapeutics Inc | Binding proteins are activated under limited conditions |
| CN109939232A (zh) * | 2017-12-21 | 2019-06-28 | 张曼 | 关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞pumc-91的应用 |
| CN109939231A (zh) * | 2017-12-21 | 2019-06-28 | 张曼 | 关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞t24的应用 |
| CN109939126A (zh) * | 2017-12-21 | 2019-06-28 | 张曼 | Cd3×b7h3双特异抗体定向杀伤耐阿霉素膀胱癌细胞pumc-91/adm的应用 |
| CN109939230A (zh) * | 2017-12-21 | 2019-06-28 | 张曼 | 关于cd3×b7h3双特异性抗体定向杀伤耐顺铂膀胱癌细胞t24/ddp的应用 |
| CN109971711A (zh) * | 2017-12-27 | 2019-07-05 | 张曼 | 关于cd3×b7h3双特异性抗体定向杀伤人膀胱癌细胞的应用 |
| CN111787949A (zh) | 2018-02-15 | 2020-10-16 | 宏观基因有限公司 | 变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途 |
| JP7724061B2 (ja) | 2018-04-11 | 2025-08-15 | インヒブルクス バイオサイエンシズ インコーポレイテッド | 制約されたｃｄ３結合を有する多重特異性ポリペプチド構築物ならびに関連する方法および使用 |
| TWI848953B (zh) | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| TW202035451A (zh) | 2018-07-24 | 2020-10-01 | 美商英伊布里克斯公司 | 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法 |
| CN109762068A (zh) * | 2018-08-09 | 2019-05-17 | 源道隆（苏州）医学科技有限公司 | 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用 |
| CN120623346A (zh) | 2018-10-11 | 2025-09-12 | 因荷布瑞克斯生物科学公司 | Pd-1单结构域抗体及其治疗组合物 |
| US20230124851A1 (en) | 2018-10-11 | 2023-04-20 | Inhibrx, lnc. | B7h3 single domain antibodies and therapeutic compositions thereof |
| TW202033218A (zh) * | 2018-12-07 | 2020-09-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 多特異性蛋白分子 |
| CA3121565A1 (en) * | 2018-12-07 | 2020-06-11 | Jiangsu Hengrui Medicine Co., Ltd. | Cd3 antibody and pharmaceutical use thereof |
| KR102732027B1 (ko) * | 2019-07-09 | 2024-11-20 | 주식회사 와이바이오로직스 | B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도 |
| CN111454357B (zh) * | 2019-08-14 | 2022-03-15 | 康诺亚生物医药科技（成都）有限公司 | 一种含有抗体的肿瘤治疗剂的开发和应用 |
| EP3822288A1 (en) * | 2019-11-18 | 2021-05-19 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof |
| KR20220119694A (ko) * | 2019-12-23 | 2022-08-30 | 마크로제닉스, 인크. | 암 치료를 위한 요법 |
| IL294879A (en) | 2020-01-29 | 2022-09-01 | Inhibrx Inc | Monodomain antibodies of cd28 and their multivalent and multispecific constructs |
| WO2022232392A2 (en) * | 2021-04-28 | 2022-11-03 | Lyvgen Biopharma Holdings Limited | Bi-specific antibodies comprising anti-b7h3 binding molecules |
| CN113527493B (zh) * | 2021-07-20 | 2023-10-27 | 广州爱思迈生物医药科技有限公司 | 一种b7-h3抗体及其应用 |
| US20230151095A1 (en) | 2021-11-12 | 2023-05-18 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
| CN114539420B (zh) * | 2022-01-20 | 2024-05-17 | 荣昌生物制药(烟台)股份有限公司 | 抗b7-h3单克隆抗体、抗b7-h3×cd3双特异性抗体、制备方法及其应用 |
| CN117903311B (zh) * | 2024-03-20 | 2024-10-25 | 湖南卓润生物科技有限公司 | sST2特异性结合蛋白及其制备方法和应用 |
| WO2025245264A1 (en) * | 2024-05-21 | 2025-11-27 | Briapro Therapeutics Corp. | Anti-b7-h3 antibodies and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12018501083A1 (en) * | 2010-03-04 | 2019-02-18 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| EA033677B1 (ru) * | 2011-05-21 | 2019-11-15 | Macrogenics Inc | Cd3-связывающие молекулы, способные к связыванию с cd3 человека и cd3, не являющимся человеческим |
| US10851178B2 (en) * | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US9487587B2 (en) * | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| US20140302037A1 (en) * | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| UA116479C2 (uk) * | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ |
| EP2839842A1 (en) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| BR112018006817A2 (pt) * | 2015-10-08 | 2018-10-23 | Macrogenics Inc | método de tratamento do câncer |
-
2016
- 2016-08-12 CA CA2995709A patent/CA2995709A1/en not_active Abandoned
- 2016-08-12 WO PCT/US2016/046680 patent/WO2017030926A1/en not_active Ceased
- 2016-08-12 PE PE2018000249A patent/PE20181066A1/es unknown
- 2016-08-12 JP JP2018508741A patent/JP2018523686A/ja active Pending
- 2016-08-12 MA MA042665A patent/MA42665A/fr unknown
- 2016-08-12 KR KR1020187007443A patent/KR20180038045A/ko not_active Withdrawn
- 2016-08-12 CN CN201680048182.7A patent/CN107921130A/zh active Pending
- 2016-08-12 EP EP16837560.8A patent/EP3337507A4/en not_active Withdrawn
- 2016-08-12 AU AU2016307955A patent/AU2016307955A1/en not_active Abandoned
- 2016-08-12 EA EA201890443A patent/EA201890443A1/ru unknown
- 2016-08-12 US US15/752,367 patent/US20190002563A1/en not_active Abandoned
- 2016-08-12 CR CR20180105A patent/CR20180105A/es unknown
- 2016-08-12 MX MX2018001954A patent/MX2018001954A/es unknown
- 2016-08-12 HK HK18109035.8A patent/HK1249423A1/zh unknown
- 2016-08-16 TW TW105126154A patent/TW201718652A/zh unknown
-
2018
- 2018-02-13 ZA ZA2018/00955A patent/ZA201800955B/en unknown
- 2018-02-15 EC ECIEPI201811248A patent/ECSP18011248A/es unknown
- 2018-02-15 CO CONC2018/0001485A patent/CO2018001485A2/es unknown
- 2018-02-15 IL IL257562A patent/IL257562A/en unknown
- 2018-02-15 PH PH12018500363A patent/PH12018500363A1/en unknown
- 2018-02-15 CL CL2018000422A patent/CL2018000422A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018523686A5 (OSRAM) | ||
| CN108473565B (zh) | Ctla4结合剂 | |
| CN109071639B (zh) | Pd1/ctla4结合剂 | |
| US12497465B2 (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| US20230110128A1 (en) | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor | |
| JP2020508317A5 (OSRAM) | ||
| JP2020183413A (ja) | Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法 | |
| AU2018263862A1 (en) | Stable formulations of programmed death receptor 1 (PD-1) antibodies and methods of use thereof | |
| CN111133005B (zh) | 程序性细胞死亡蛋白1抗体 | |
| JP2020536109A5 (OSRAM) | ||
| JP2016509582A5 (OSRAM) | ||
| IL321717A (en) | Anti-PD-1 antibodies for the treatment of lung cancer | |
| JP2009539380A5 (OSRAM) | ||
| RU2015129551A (ru) | Антитела к в7-н4 человека и их применение | |
| JP7459058B2 (ja) | Ｃｄ１３７／ｈｅｒ２二重特異性物質とｐｄ－１系阻害物質とを含む併用療法およびその使用法 | |
| JP2020529469A5 (OSRAM) | ||
| WO2023281480A1 (en) | Conjugates of checkpoint inhibitors with il-2, and uses thereof | |
| CN109663130B (zh) | Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| CN111655725A (zh) | 用于治疗癌症的组合产品 | |
| US20230032465A1 (en) | Antibody-drug conjugates specific for cd276 and uses thereof | |
| JP2016511257A (ja) | 癌の治療における抗ｇｃｃ抗体−薬物複合体及びｄｎａ損傷剤の投与 | |
| WO2024145869A1 (en) | Antibodies against axl and uses thereof | |
| JP2021531263A (ja) | 抗ヒトｐｄ−ｌ１抗体とその使用 | |
| Lacek et al. | Development of an innovative bifunctional CPL976-MMAE conjugate based on a bispecific anti-PD-L1/ant-AXL antibody with a dual mechanism of action | |
| TWI814752B (zh) | 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途 |